KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $85.9 million.

  • Emergent BioSolutions' Cost of Revenue fell 2993.47% to $85.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 14487.8%. This contributed to the annual value of $276.0 million for FY2024, which is 968.59% down from last year.
  • Emergent BioSolutions' Cost of Revenue amounted to $85.9 million in Q3 2025, which was down 2993.47% from $66.9 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Cost of Revenue high stood at $440.5 million for Q4 2021, and its period low was -$287.3 million during Q4 2024.
  • Moreover, its 5-year median value for Cost of Revenue was $92.2 million (2022), whereas its average is $77.8 million.
  • In the last 5 years, Emergent BioSolutions' Cost of Revenue crashed by 14633.37% in 2022 and then skyrocketed by 10672.45% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cost of Revenue (Quarter) stood at $440.5 million in 2021, then tumbled by 146.33% to -$204.1 million in 2022, then decreased by 5.19% to -$214.7 million in 2023, then plummeted by 33.81% to -$287.3 million in 2024, then skyrocketed by 129.9% to $85.9 million in 2025.
  • Its last three reported values are $85.9 million in Q3 2025, $66.9 million for Q2 2025, and $88.5 million during Q1 2025.